Stock Screener
US stocks rated by the Lician Quant model: a 1–5 rating and A+ to F grades for valuation, growth, profitability, momentum and EPS revisions, each against the stock’s sector. Filter, sort by any factor and share the URL.
73 stocks · Strong Buy or Buy · Healthcare · Momentum ≥ A-
| Stock | Quant ratingRating | ValuationVal | GrowthGrow | ProfitabilityProf | MomentumMom | EPS revisionsRev | Market capMkt cap | P/EP/E | Revenue growthRev YoY | Div. yieldYield | Short % floatShort | Next earningsEarnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1AVAHAveanna Healthcare Holdings Inc | 4.99Strong Buy | A | A- | B+ | A | A+ | $2.9B | 10.6 | +19.5% | — | 10.2% | Nov 12 |
| 2CDNACareDx Inc | 4.98Strong Buy | C+ | B+ | A+ | A+ | A+ | $3.6B | 32.2 | +34.4% | — | 13.6% | — |
| 3HALOHalozyme Therapeutics Inc | 4.97Strong Buy | C | B+ | A+ | A+ | A+ | $14.7B | 35.4 | +41.2% | — | 11.2% | Nov 5 |
| 4OSCROscar Health Inc | 4.97Strong Buy | — | A | A- | A | B- | — | — | +42.8% | — | — | Nov 5 |
| 5BTSGBrightSpring Health Services, Inc. Common Stock | 4.96Strong Buy | A- | A- | B- | A | — | $11.6B | 28.4 | +22.9% | — | 12.0% | — |
| 6REGNRegeneron Pharmaceuticals Inc | 4.95Strong Buy | B+ | C+ | A+ | A | A | $103B | 21.5 | +18.6% | — | 2.1% | — |
| 7PACSPACS Group, Inc. | 4.94Strong Buy | B+ | A | A- | A | B | $7.6B | 28.1 | +16.6% | — | — | — |
| 8CONConcentra Group Holdings Parent, Inc. | 4.94Strong Buy | A- | B- | A- | A+ | B | $5.0B | 25.4 | +14.0% | 0.99% | 3.1% | Nov 5 |
| 9ARQTArcutis Biotherapeutics Inc | 4.92Strong Buy | C+ | A+ | A- | A- | B+ | $3.9B | 137.4 | +76.1% | — | 23.9% | Nov 4 |
| 10KNSAKiniksa Pharmaceuticals Ltd | 4.89Strong Buy | B- | A+ | A | A+ | C | $4.1B | 37.7 | +58.2% | — | 9.6% | — |
| 11OMEROmeros Corporation | 4.86Strong Buy | C | — | — | A- | A+ | $1.2B | 9.6 | — | — | 20.4% | Nov 12 |
| 12VEEVVeeva Systems Inc Class A | 4.85Strong Buy | C+ | B | A+ | A | B+ | $50.6B | 49.9 | +16.5% | — | — | Nov 19 |
| 13AMNAMN Healthcare Services Inc | 4.83Strong Buy | A+ | D+ | B- | A+ | A- | $1.6B | 14.9 | +24.0% | — | 10.0% | Nov 5 |
| 14RIGLRigel Pharmaceuticals Inc | 4.82Strong Buy | A+ | B+ | A+ | A | D- | $895M | 2.8 | +3.3% | — | 18.3% | Nov 5 |
| 15ETONEton Pharmaceuticals Inc | 4.80Strong Buy | D+ | A+ | A- | A- | A- | $1.4B | 113.6 | +81.5% | — | 9.3% | Nov 5 |
| 16MEDPMedpace Holdings Inc | 4.78Strong Buy | B- | B+ | A+ | A- | B- | $17.3B | 35.2 | +24.7% | — | 7.2% | — |
| 17AMGNAmgen Inc | 4.76Strong Buy | B | B- | A+ | A | C+ | $250B | 28.6 | +9.1% | 2.80% | 2.5% | — |
| 18WATWaters Corporation | 4.76Strong Buy | B- | B+ | B | A- | B+ | $45.2B | 271.9 | +502.1% | — | 5.4% | — |
| 19BLCOBausch + Lomb Corp | 4.70Strong Buy | A- | C | B | A- | A | $5.9B | NM | +8.9% | — | — | — |
| 20HAEHaemonetics Corporation | 4.70Strong Buy | B+ | C- | B+ | A+ | B+ | $5.4B | 56.1 | +0.4% | — | 7.6% | Nov 5 |
| 21EXELExelixis Inc | 4.69Strong Buy | C+ | B | A+ | A+ | C- | $17.5B | 19.7 | +9.1% | — | 13.4% | — |
| 22PCRXPacira BioSciences, Inc. | 4.67Strong Buy | A | D | B+ | A | B+ | $1.4B | 98.9 | +5.7% | — | — | Nov 5 |
| 23WSTWest Pharmaceutical Services Inc | 4.66Strong Buy | C+ | C+ | A- | A- | A- | $28.7B | 44.9 | +12.6% | — | 2.8% | — |
| 24LLYEli Lilly and Company | 4.65Strong Buy | — | A | A+ | A+ | F | — | — | +45.5% | 0.56% | — | — |
| 25RPRXRoyalty Pharma Plc | 4.64Strong Buy | B+ | D+ | A | A | B- | $28.0B | 34.4 | +10.0% | — | 3.5% | Nov 4 |
Showing 25 of 73
Source: Lician Quant Grades (SEC EDGAR statements, EODHD prices and estimates); short interest: FINRA; earnings dates: earnings calendar; dividend yield: EODHD fundamentals · Quant run Nov 4, 2026
Grades rank each stock against its sector peers; they are not investment advice. How the rating and grades work · Short interest · Earnings calendar